← Back to Search

Senolytic Drug

Fisetin for COVID-19 (COVID-FIS Trial)

Phase 2
Waitlist Available
Led By James L Kirkland, MD, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
CoV severity of moderate or less OR SpO2 ≥ 85% (on room air or ≤ 2 L of supplemental oxygen at time of enrollment)
Current nursing home resident
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 2, 7, 10, 14, 17, 30, 90 and 180
Awards & highlights

COVID-FIS Trial Summary

This trial will test whether Fisetin can help prevent progression of the disease and reduce complications from coronavirus.

Who is the study for?
This trial is for nursing home residents aged 65 or older who have moderate or less severe COVID-19, confirmed by a PCR test within the last 10 days. Participants must be able to consent and have functioning major organs. Those with certain severe health conditions, participating in other COVID-19 treatment trials, or with allergies to Fisetin are excluded.Check my eligibility
What is being tested?
The study is testing if Fisetin can prevent worsening of COVID-19 symptoms and reduce complications from excessive inflammation. It's a pilot study where participants will either receive Fisetin or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
While not specified here, potential side effects may include allergic reactions to Fisetin and typical drug-related issues such as gastrointestinal discomfort, headaches, dizziness, or skin rashes.

COVID-FIS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My COVID-19 symptoms are moderate or less, or my oxygen levels are 85% or higher.
Select...
I currently live in a nursing home.
Select...
I am a man or a post-menopausal woman aged 65 or older.

COVID-FIS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 2, 7, 10, 14, 17, 30, 90 and 180
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 2, 7, 10, 14, 17, 30, 90 and 180 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in COVID-19 Severity

Side effects data

From 2022 Phase 2 trial • 55 Patients • NCT04771611
7%
Rash
7%
hyperhidrosis
7%
Chest pain
7%
Diarrhea
7%
Sinusitis
7%
Infectious Rash
7%
Back Pain
7%
Headache
7%
Worsening Headache
7%
Dyspnea
7%
sore throat
3%
hypertension
3%
tachycardia
3%
amnesia
3%
asthma with exacerbation
3%
Anosmia
3%
migraine
3%
conjunctivitis
3%
rhinitis
3%
flu like symptoms
3%
Otitis media
3%
vertigo
3%
edema, hand, bilateral
3%
bacterial vaginosis
3%
ear pain, left
3%
cough
3%
Upper Respiratory Infection
3%
Epistaxis
3%
flatulence
3%
shortness of breath
3%
arthoplasty
3%
ageusia
3%
change in smell
3%
vomiting
3%
fatigue
3%
Colic Renal
3%
Nephrolithiasis Calcium Oxalate
3%
sneezing
3%
thrush
3%
right shoulder arthroscopy, rotator cuff, repair
3%
watering eyes (epiphora)
3%
Systolic murmur
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment Group
Placebo

COVID-FIS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment GroupExperimental Treatment1 Intervention
Subjects will receive treatment drug (Fisetin)
Group II: Placebo GroupPlacebo Group1 Intervention
Subjects will receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fisetin
2016
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,206 Previous Clinical Trials
3,767,063 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,669 Previous Clinical Trials
28,005,094 Total Patients Enrolled
James L Kirkland, MD, PhDPrincipal InvestigatorMayo Clinic
4 Previous Clinical Trials
215 Total Patients Enrolled

Media Library

Fisetin (Senolytic Drug) Clinical Trial Eligibility Overview. Trial Name: NCT04537299 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this a full clinical trial or are there still positions available for participants?

"Unfortunately, this trial is not presently looking for new patients according to the information found on clinicaltrials.gov. Although the study's last update was on March 7th, 2022, it originally posted on January 25th of that year. There are 1151 other trials enrolling participants at this time though."

Answered by AI

When can consumers expect to see Fisetin available for purchase?

"Fisetin received a score of 2 because, while there is data indicating that it is safe, there is no evidence yet supporting that it is an effective treatment."

Answered by AI

What else is known about the effects of Fisetin?

"There are seven Fisetin studies open at the moment, none of which have reached Phase 3 yet. The vast majority of these trials are taking place in Vail, Colorado; however, there are 7 clinical locations in total running these experiments."

Answered by AI

How many individuals are being recruited for this research project?

"Unfortunately, this study is no longer seeking patients for the trial. The listing was created on January 25th, 2022 but was last updated on March 7th, 2022. However, there are 1144 other trials actively recruiting patients with covid19 and 7 trials for Fisetin that are currently enrolling participants."

Answered by AI
~3 spots leftby Aug 2024